TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00852956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betahistine
Description: The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine
Description: The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00
Study: NCT00686790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (PegIntron, SCH 54031)
Description: Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
Study: NCT03774927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 Hz treatment group
Description: 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz treatment group
Description: 20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
Study: NCT01450579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7373
Description: Intermuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7373
Description: Intermuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7373
Description: Intermuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study: NCT03644602

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAPs diet
Description: Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAPs diet
Description: Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAPs diet
Description: Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)
Study: NCT04323436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spartalizumab placebo
Description: dextrose 5% in water (D5W) for infusion
Study: NCT02848417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions.
Study: NCT00760864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-715 and methotrexate
Description: TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-715 and methotrexate
Description: TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-715 and methotrexate
Description: TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
Study: NCT02399579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provocation test
Description: The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
Study: NCT01178853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin 5 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin 5 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
Description: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
Description: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
Description: Warfarin 5 mg + Pitavastatin 4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
Description: Warfarin 5 mg + Pitavastatin 4mg
Study: NCT04110808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypotensive anaesthesia using Nitroglycerine
Description: effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.

Intervention type: DRUG
Group type: OTHER
Intervention: hypotensive anaesthesia using Nitroglycerine
Description: effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure.
Study: NCT03999619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 2 Learn
Description: 10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Move 2 Learn
Description: 10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
Study: NCT01316367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRECEDE HPE model
Description: The model considers the influence of the following three factors on health-related behavior:~* Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~* Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~* Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHPE
Description: The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
Study: NCT03563495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tissue engineered group
Description: cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autogenous bone graft group
Study: NCT03815851

Intervention type: DEVICE
Group type: OTHER
Intervention: prophylactic drainage
Description: place prophylactic drainage after surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: no prophylactic drainage
Description: Not place prophylactic drainage after surgery
Study: NCT04343989

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
Study: NCT02539602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Need to Know students received the N2K curriculum as described previously
Study: NCT01396122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System
Description: Perform surgery with GYNECARE PROSIMA\* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
Study: NCT02161393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation Programme
Description: This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
Study: NCT02873442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cells
Description: DC cell suspension (1×107 DC+ physiological saline~+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT02956915

Intervention type: PROCEDURE
Intervention: Transfemoral Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
Study: NCT02409732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid hydrochloride
Study: NCT02621827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral dose of stable isotope labeled 25(OH)D3
Description: At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
Study: NCT02409732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with blue light
Study: NCT00306735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Study: NCT03320941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as tablets to be taken daily orally.
Study: NCT01090076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
Description: Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
Description: Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
Study: NCT02674971

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common components of intervention
Description: 12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common components of intervention
Description: 12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
Study: NCT03877133

Intervention type: DEVICE
Group type: OTHER
Intervention: Near-infrared spectroscopy
Description: Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
Study: NCT02321371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose + Rifaximin
Description: Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Continuation of Lactulose therapy for further 48 hours.
Study: NCT00553800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT00513565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose
Description: Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
Study: NCT01877720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive respiratory support with NAVA mode and PSV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive respiratory support with NAVA mode and PSV
Study: NCT02920216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
Study: NCT00513565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single dose
Description: Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
Study: NCT04263909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Tablet
Description: sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
Study: NCT00357747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEG35156
Description: After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
Study: NCT00513565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: single dose
Description: Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
Study: NCT01180842

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga treatment program
Description: yoga program designed specifically for the patient with CF
Study: NCT04166019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led self-management program
Description: The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
Study: NCT02332096

Intervention type: DEVICE
Intervention: Home Sleep Testing Device
Description: Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.